| 31.39 1.36 (4.53%) | 10-07 11:35 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 37.88 | 1-year : | 39.87 |
| Resists | First : | 32.43 | Second : | 34.13 |
| Pivot price | 30.78  |
|||
| Supports | First : | 29.67 | Second : | 24.68 |
| MAs | MA(5) : | 30.72 |
MA(20) : | 31.03 |
| MA(100) : | 32.92 |
MA(250) : | 32.87 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 22.9 |
D(3) : | 38 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 44 | Low : | 19.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VTVT ] has closed above bottom band by 17.1%. Bollinger Bands are 57.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 31.57 - 31.78 | 31.78 - 31.96 |
| Low: | 29.89 - 30.09 | 30.09 - 30.26 |
| Close: | 30.03 - 30.36 | 30.36 - 30.63 |
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Wed, 07 Oct 2026
vTv Therapeutics (VTVT) Completes Enrollment for Phase 3 Trial o - GuruFocus
Wed, 07 Oct 2026
vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Tue, 06 Oct 2026
A cellist will join diabetes experts to discuss low blood sugar in type 1 diabetes - Stock Titan
Mon, 05 Oct 2026
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) - The Manila Times
Mon, 05 Oct 2026
A type 1 diabetes drug trial has enrolled 166 people. Results are expected in mid-2027. - Stock Titan
Wed, 23 Sep 2026
vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Below 50 Day Moving Average - Here's What Happened - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 38.8 (%) |
| Held by Institutions | 40.7 (%) |
| Shares Short | 166 (K) |
| Shares Short P.Month | 172 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.34 |
| Profit Margin | -13 % |
| Operating Margin | -25.2 % |
| Return on Assets (ttm) | -10.2 % |
| Return on Equity (ttm) | -15.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 2.06 |
| Sales Per Share | 9.32 |
| EBITDA (p.s.) | -2.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -40.05 |
| PEG Ratio | 0 |
| Price to Book value | 4.73 |
| Price to Sales | 3.21 |
| Price to Cash Flow | -7.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|